IN2014MN00380A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00380A
IN2014MN00380A IN380MUN2014A IN2014MN00380A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A IN 380MUN2014 A IN380MUN2014 A IN 380MUN2014A IN 2014MN00380 A IN2014MN00380 A IN 2014MN00380A
Authority
IN
India
Prior art keywords
comparising
nanoparticles
producing
composition
active compound
Prior art date
Application number
Other languages
English (en)
Inventor
Cammarano Raffaele
Meiser Felix
Postma Almar
Caruso Frank
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006903527A external-priority patent/AU2006903527A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of IN2014MN00380A publication Critical patent/IN2014MN00380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN380MUN2014 2006-06-30 2007-06-29 IN2014MN00380A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006903527A AU2006903527A0 (en) 2006-06-30 Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form
US91595507P 2007-05-04 2007-05-04
PCT/AU2007/000910 WO2008000042A1 (en) 2006-06-30 2007-06-29 Methods for the preparation of biologically active compounds in nanoparticulate form

Publications (1)

Publication Number Publication Date
IN2014MN00380A true IN2014MN00380A (OSRAM) 2015-06-19

Family

ID=38845051

Family Applications (1)

Application Number Title Priority Date Filing Date
IN380MUN2014 IN2014MN00380A (OSRAM) 2006-06-30 2007-06-29

Country Status (9)

Country Link
US (4) US20150164802A1 (OSRAM)
EP (1) EP2054042B8 (OSRAM)
JP (4) JP5508003B2 (OSRAM)
AU (1) AU2007264418B2 (OSRAM)
CA (2) CA2653384C (OSRAM)
DK (1) DK2054042T3 (OSRAM)
IL (2) IL195945A (OSRAM)
IN (1) IN2014MN00380A (OSRAM)
WO (1) WO2008000042A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054042B8 (en) 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
MX351930B (es) * 2009-04-24 2017-11-03 Iceutica Pty Ltd Una formulacion novedosa de indometacina.
EP2421512A4 (en) * 2009-04-24 2013-01-23 Iceutica Pty Ltd NEW NAPROXE FORMULATION
CN102740835A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
CN104000785B (zh) * 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
EA201171282A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
AU2014202776B2 (en) * 2009-04-24 2016-02-25 Iceutica Pty Ltd A Novel Formulation of Indomethacin
AU2016200397B2 (en) * 2009-04-24 2017-08-17 Iceutica Pty Ltd A Novel Formulation of Indomethacin
CA2759102A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A herbicidal composition having high volume fraction of mancozeb
KR20170075024A (ko) * 2009-04-24 2017-06-30 아이슈티카 피티와이 리미티드 신규 멜록시캄 제제
EA201171280A1 (ru) 2009-04-24 2012-09-28 Айсьютика Пти Лтд. Способ улучшения характеристик растворения биологически активного материала
AU2014208310C1 (en) * 2009-04-24 2020-01-23 Iceutica Pty Ltd A Novel Formulation of Diclofenac
MA33295B1 (fr) * 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation de diclofénac
AU2014201967B2 (en) * 2009-04-24 2015-09-17 Iceutica Pty Ltd A Novel Formulation of Naproxen
PH12015501811A1 (en) * 2009-04-24 2019-03-25 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
SG177281A1 (en) * 2009-06-19 2012-02-28 Nanoform Hungary Ltd Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
EP2515874B1 (en) * 2009-12-22 2014-08-20 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
US9695390B2 (en) 2010-08-23 2017-07-04 President And Fellows Of Harvard College Acoustic waves in microfluidics
WO2012027378A2 (en) * 2010-08-23 2012-03-01 President And Fellows Of Harvard College Particles for drug delivery and other applications
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
JP2016507542A (ja) 2013-02-08 2016-03-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 反応型噴霧乾燥による無機／有機複合材料の製造
US9138381B2 (en) 2013-02-08 2015-09-22 Basf Se Production of inorganic-organic composite materials by reactive spray-drying
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HU231309B1 (hu) * 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
KR101742152B1 (ko) * 2014-02-27 2017-06-01 바로돈에스에프주식회사 비특이성 면역증강제 조성물 및 그 제조방법, 그리고 그 용도
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US10258987B2 (en) 2014-06-26 2019-04-16 President And Fellows Of Harvard College Fluid infection using acoustic waves
EP3341116B1 (en) 2015-08-27 2022-03-16 President and Fellows of Harvard College Sorting method using acoustic waves
CN110035756A (zh) * 2016-11-30 2019-07-19 成药技术Ip控股有限公司 含有他达拉非的药物配制品
US11701658B2 (en) 2019-08-09 2023-07-18 President And Fellows Of Harvard College Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves
EP4171515A1 (en) * 2020-06-25 2023-05-03 Omya International AG Co-ground active(s) comprising product comprising surface-reacted calcium carbonate

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
GB8328929D0 (en) 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
CA2143263C (en) 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
EP0952770A4 (en) * 1995-09-07 1999-12-22 Fuisz Technologies Ltd SYSTEM FOR MAKING SUBSTANTIALLY NON-SOLUBLE BIOALTERANT AGENTS BIOAVAILABLE
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
NZ502990A (en) 1997-08-27 2002-02-01 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
EA200000956A1 (ru) 1998-04-18 2001-04-23 Глаксо Груп Лимитед Фармацевтический аэрозольный препарат
AUPP355798A0 (en) 1998-05-15 1998-06-11 University Of Western Australia, The Process for the production of ultrafine powders
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド 徐放性ナノ粒子組成物
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
ES2325057T3 (es) * 2000-08-31 2009-08-25 Jagotec Ag Particulas molturadas.
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE60137362D1 (de) * 2000-11-20 2009-02-26 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
EP2283818B1 (en) 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
NZ534234A (en) 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US20070059356A1 (en) 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4123834B2 (ja) 2002-06-10 2008-07-23 株式会社ダイフク 移載設備
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US7964734B2 (en) 2002-09-30 2011-06-21 A/S Gea Farmaceutisk Fabrik Raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
WO2004058216A2 (en) 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
WO2005016310A1 (en) 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
JP2007507339A (ja) 2003-10-01 2007-03-29 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 粒子製造装置及び方法
WO2006009419A1 (es) 2004-07-19 2006-01-26 Luis Cordova Boone Neumáticos con doble banda de rodamiento
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (en) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Pharmaceutical dosage form comprising meloxicam
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP6091041B2 (ja) * 2004-12-31 2017-03-08 イシューティカ ピーティーワイ リミテッド ナノ粒子組成物及びその合成方法
CA2631494A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
JP2009519970A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2054042B8 (en) 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
NZ705763A (en) 2006-06-30 2016-10-28 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
JP2010167968A (ja) 2009-01-23 2010-08-05 Mitsubishi Fuso Truck & Bus Corp 床構造
CN104000785B (zh) 2009-04-24 2021-01-05 伊休蒂卡有限公司 美他沙酮的新剂型
EA201171282A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
MA33295B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation de diclofénac
CA2759102A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A herbicidal composition having high volume fraction of mancozeb
EA201171280A1 (ru) 2009-04-24 2012-09-28 Айсьютика Пти Лтд. Способ улучшения характеристик растворения биологически активного материала
CN102740835A (zh) 2009-04-24 2012-10-17 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
EP2421512A4 (en) 2009-04-24 2013-01-23 Iceutica Pty Ltd NEW NAPROXE FORMULATION
MX351930B (es) 2009-04-24 2017-11-03 Iceutica Pty Ltd Una formulacion novedosa de indometacina.
KR20170075024A (ko) 2009-04-24 2017-06-30 아이슈티카 피티와이 리미티드 신규 멜록시캄 제제

Also Published As

Publication number Publication date
JP2014058524A (ja) 2014-04-03
CA2653384A1 (en) 2008-01-03
CA2653384C (en) 2017-03-14
JP2018058846A (ja) 2018-04-12
IL243534B (en) 2021-03-25
JP5508003B2 (ja) 2014-05-28
IL243534A0 (en) 2016-02-29
US11103456B2 (en) 2021-08-31
DK2054042T3 (da) 2020-08-03
US20180369145A1 (en) 2018-12-27
US20220054418A1 (en) 2022-02-24
US20150164802A1 (en) 2015-06-18
EP2054042A4 (en) 2012-08-15
JP6651489B2 (ja) 2020-02-19
IL195945A (en) 2016-02-29
IL195945A0 (en) 2009-09-01
EP2054042B1 (en) 2020-04-29
US20240122855A1 (en) 2024-04-18
AU2007264418A1 (en) 2008-01-03
EP2054042B8 (en) 2020-06-10
CA2960377A1 (en) 2008-01-03
WO2008000042A1 (en) 2008-01-03
EP2054042A1 (en) 2009-05-06
JP2016026220A (ja) 2016-02-12
JP2009541362A (ja) 2009-11-26
AU2007264418B2 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
IN2014MN00380A (OSRAM)
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
AP2914A (en) Method for producing 4-oxoquinoline compound
UA103794C2 (en) Liposome composition
SG171584A1 (en) Nanoparticulate metal boride composition and its use for identification- marking plastic parts
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
WO2008051465A3 (en) Process for making crystalline anhydrous docetaxel
NZ593874A (en) Nalmefene hydrochloride dihydrate
TN2012000248A1 (en) Novel spiropiperidine compounds
EP2060349A4 (en) METHOD FOR MANUFACTURING HOLE DISCHARGING
EP2132013A4 (en) THIN METAL NANODRESSES MANUFACTURED BY BIOTEMPLATING
SG143149A1 (en) Phosphite composition and method for producing the same
EP2103603A4 (en) PROCESS FOR PREPARING A PYRROLIDINE COMPOUND
IL192788A0 (en) Method for producing steroid compound
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
IL193137A0 (en) Method of characterizing a biologically active compound
EP2061778A4 (en) METHOD FOR PRODUCING A CYCLIC UNSATURATED COMPOUND
EP2261317B8 (en) Microorganism producing cyclic compound
SG146569A1 (en) Process for producing methionine
IL192702A0 (en) Process for producing 5-alkoxy-4-hydroxymethylpyrazole compound
ZA200807547B (en) Method for producing 4-oxoquinoline compound
TW200740772A (en) Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine
EP2039698A4 (en) PHOSPHORUS MOLYBDENUM COMPOUND AND PROCESS FOR PRODUCING THE SAME
SG136932A1 (en) Method for producing a layer structure
EP2050735A4 (en) METHOD FOR PRODUCING AN OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND